Ann Doan Bass MD
Neuroimmunology/Multiple Sclerosis
MS Clinic Medical Director
Join to View Full Profile
525 Oak Centre DrSuite 320San Antonio, TX 78258
Phone+1 210-490-0016
Fax+1 210-490-3010
Dr. Bass is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- I am a board-certified neurologist specializing in the diagnosis, treatment, and management of multiple sclerosis and other CNS demyelinating diseases. I am the Medical Director of the comprehensive MS clinic and research center at Lone Star Neurology of San Antonio, which is affiliated with the National Multiple Sclerosis Society.
Clinical Expertise
- Multiple sclerosis, Demyelinating diseases, Neuroimmunology (Multiple sclerosis)
Education & Training
University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineResidency, Neurology, 1994 - 1997- University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineInternship, Internal Medicine, 1993 - 1994
- The University of Texas Health Science Center at San AntonioClass of 1993
Certifications & Licensure
TX State Medical License 1995 - 2026
National Board of Physicians and Surgeons Neurology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification Centricity Practice Solution, GE Healthcare, 2013-2014, 2016
- CMS Meaningful Use Stage 2 Certification ezAccess Patient Portal, Medical Office Technologies, Inc., 2013-2014, 2016
- CMS Meaningful Use Stage 1 Certification Centricity Practice Solution, GE Healthcare, 2013-2014, 2016
Clinical Trials
- A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS (MASTER-2) Start of enrollment: 2019 Jul 22
Roles: Principal Investigator
- Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls. Start of enrollment: 2022 Jan 25
- A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis Start of enrollment: 2022 May 03
Publications & Presentations
PubMed
- 1 citationsLong-term efficacy and safety of alemtuzumab in participants with highly active MS: TOPAZ clinical trial and interim analysis of TREAT-MS real-world study.Tjalf Ziemssen, Ann D Bass, Bart Van Wijmeersch, Sara Eichau, Stephan Richter
Therapeutic Advances in Neurological Disorders. 2025-01-01 - 19 citationsAutoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data.Alasdair J Coles, Joanne L Jones, Patrick Vermersch, Anthony Traboulsee, Ann D Bass
Multiple Sclerosis. 2022-04-01 - The sequential natalizumab - alemtuzumab therapy in patients with relapsing forms of multiple sclerosis (SUPPRESS) trial - Part I: Rationale and objectives.Rehana Z Hussain, Peter V Sguigna, Annette Okai, Crystal Wright, Mariam Madinawala
Journal of Central Nervous System Disease. 2022-01-01
Abstracts/Posters
- Efficacy of a fourth alemtuzumab course in RRMS patients from CARE-MS II who experienced disease activity after three prior coursesTraboulsee A, Alroughani R, Boster A, Bass A, Berkovich R, Fernandez O, Kim H-J, Limmroth V, Lycke J, Macdonell RAL, Singer BA, Vermersch P, Wiendl H, Ziemssen T, Mela..., 53rd CNSF Congress 2018, Halifax, Nova Scotia, Canada, 6/24/2018
- Efficacy of a Fourth Alemtuzumab Course in RRMS Patients With Disease Activity After Three Prior Courses: Analysis of CARE-MS IHeinz Wiendl1, Raed Alroughani2, Aaron Boster3, Anthony Traboulsee4, Ann D Bass5, Regina Berkovich6, Giancarlo Comi7, Óscar Fernández8, Ho Jin Kim9, Volker Limmroth10,..., EAN 2018, Lisbon, Portugal, 6/16/2018
- Efficacy of a Fourth Alemtuzumab Course in RRMS Patients With Disease Activity After Three Prior Courses: Analysis of CARE-MS IIBarry A Singer1, Raed Alroughani2, Aaron Boster3, Ann D Bass4, Regina Berkovich5, Giancarlo Comi6, Óscar Fernández7, Ho Jin Kim8, Volker Limmroth9, Jan Lycke10, Richar..., CMSC 2018, Nashville, TN, 5/30/2018
Press Mentions
Merck Shares Advances in MS Portfolio with Key Efficacy and Safety Data at AAN 2022March 31st, 2022- EMD Serono Shares Advances in MS Portfolio with Key Efficacy and Safety Data at AAN 2022March 31st, 2022
Woman Learns to Embrace Life with Relapsing Multiple Sclerosis (MS)May 29th, 2019
Professional Memberships
- Member
- Texas Neurological SocietyMember
- National Multiple Sclerosis SocietyMember
- Member
- Consortium of Multiple Sclerosis CentersMember
Other Languages
- Vietnamese
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
